AMENDMENT

In the Claims:

Please replace the presently pending claims with the following claims:

1. (Five times amended) A compound according to Formula I:



$$Y—W(CR^1R^2)_nArCR^3R^4N(R^5)(CR^6R^7)_{n'}R^8 \qquad (I)$$

wherein, W is a nitrogen atom and Y is void or, W is a carbon atom and Y=H;

R^1 to R^7 may be the same or different and are independently hydrogen or straight, branched or cyclic $C_{1\text{-}6}$ alkyl;

R^8 is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in ring A or B is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a $(CH_2)_{n''}$ group (where n''= 1-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted $C_{1\text{-}6}$ alkyl group; an optionally substituted aromatic or heterocyclic group; a $C_{1\text{-}6}$ alkyl

group substituted with an optionally substituted aromatic or heterocyclic group; an optionally substituted amino group; an optionally substituted C_{1-6} alkylamino or C_{3-7} cycloalkylamino group; a sulfonyl group and an optionally substituted carbonyl group; or

the pharmaceutically acceptable acid addition salts thereof;

including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof;

wherein Ring B is selected from the group consisting of: benzene and a 5 to 7-membered cycloalkyl ring; and the optionally substituted forms thereof, or

Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

2. The compound of claim 1, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

Please cancel claim 3.

3 4. The compound of claim 1, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

4 6. The compound of claim 1, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

5 7. The compound of claim 1, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

12. (Twice amended) The compound of claim 1 wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

13. The compound of claim 12, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC_{1-4}alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

51. The compound of claim 1, wherein Z is an optionally substituted C_{1-6}alkyl group, wherein said C_{1-6}alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

55. The compound of claim 1, wherein Z is an optionally substituted aromatic or heterocyclic group or a C_{1-6}alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

56. (Amended) The compound of claim 55, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

57. The compound of claim 56, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole, benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole, oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline, piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine,

imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

58. (Twice amended) The compound of claim 57, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

98. (Twice amended) A compound selected from the group consisting of:

(a) AMD8862, N-(2-pyridinylmethyl)-N'-[2-[(1*H*-imidazol-4-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzene dimethanamine;

(b) AMD8887, N-(2-pyridinylmethyl)-N'-[2-[(1*H*-imidazol-2-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(c) AMD8816, N-(2-pyridinylmethyl)-N'-[2-(phenylureido)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(d) AMD8737, N-(2-pyridinylmethyl)-N'-[[N"-(n-butyl)carboxamido]methyl] -N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(e) AMD8739, N-(2-pyridinylmethyl)-N'-(carboxamidomethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(f) AMD8752, N-(2-pyridinylmethyl)-N'-[(N"-phenyl)carboxamidomethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(g) AMD8765, N-(2-pyridinylmethyl)-N'-(carboxymethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(h) AMD8715, N-(2-pyridinylmethyl)-N'-(phenylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(i) AMD8907, N-(2-pyridinylmethyl)-N'-(1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(j) AMD8927, N-(2-pyridinylmethyl)-N'-(5,6-dimethyl-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine (hydrobromide salt);

(k) AMD8926, N-(2-pyridinylmethyl)-N'-(5-nitro-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(l) AMD8929, N-(2-pyridinylmethyl)-N'-[(1*H*)-5-azabenzimidazol-2-ylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(m) AMD8931, N-(2-pyridinylmethyl)-N-(4-phenyl-1*H*-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(n) AMD8783, N-(2-pyridinylmethyl)-N'-[2-(2-pyridinyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(o) AMD8764, N-(2-pyridinylmethyl)-N'-(2-benzoxazolyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(p) AMD8780, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclohexyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(q) AMD8818, N-(2-pyridinylmethyl)-N'-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(r) AMD8829, N-(2-pyridinylmethyl)-N'-(3-phenylpropyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(s) AMD8839, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclopentyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(t) AMD8726, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-glycinamide;

(u) AMD8738, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-alaninamide;

(v) AMD8749, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-aspartamide;

(w) AMD8750, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-pyrazinamide;

(x) AMD8740, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-prolinamide;

(y) AMD8741, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-lysinamide;

(z) AMD8724, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-benzamide;

(aa) AMD8725, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-picolinamide;

(bb) AMD8713, N'-Benzyl-N-[[4-[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;

(cc) AMD8712, N'-phenyl-N-[[4-[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;

(dd) AMD8716, N-(6,7,8,9-tetrahydro-5*H*-cyclohepta[*bacteria*pyridin-9-yl)-4-[[(2-pyridinylmethyl)amino]methyl]benzamide;

(ee) AMD8717, N-(5,6,7,8-tetrahydro-8-quinolinyl)-4-[[(2-pyridinylmethyl)amino]methyl]benzamide;

(ff) AMD8634, N,N'-bis(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(gg) AMD8774, N,N'-bis(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5*H*-cyclohepta[*bacteria*pyridin-9-yl)-1,4-benzenedimethanamine;

(hh) AMD8775, N,N'-bis(2-pyridinylmethyl)-N'-(6,7-dihydro-5*H*-cyclopenta[*bacteria*pyridin-7-yl)-1,4-benzenedimethanamine;

(ii) AMD8819, N,N'-bis(2-pyridinylmethyl)-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)-1,4-benzenedimethanamine;

(jj) AMD8768, N,N'-bis(2-pyridinylmethyl)-N'-[(5,6,7,8-tetrahydro-8-quinolinyl)methyl]-1,4-benzenedimethanamine;

(kk) AMD8767, N,N'-bis(2-pyridinylmethyl)-N'[(6,7-dihydro-5*H*-cyclopenta[*bacteria*pyridin-7-yl)methyl]-1,4-benzenedimethanamine;

(ll) AMD8838, N-(2-pyridinylmethyl)-N-(2-methoxyethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(mm) AMD8871, N-(2-pyridinylmethyl)-N-[2-(4-methoxyphenyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(nn) AMD8844, N,N'-bis(2-pyridinylmethyl)-1,4-(5,6,7,8-tetrahydro-8-quinolinyl)benzenedimethanamine;

(oo) AMD7129, N-[(2,3-dimethoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(pp) AMD7130, N,N'-bis(2-pyridinylmethyl)-N-[1-(N"-phenyl-N"-methylureido)-4-piperidinyl]-1,3-benzenedimethanamine;

(qq) AMD7131, N,N'-bis(2-pyridinylmethyl)-N-[N"-p-toluenesulfonylphenylalanyl)-4-piperidinyl]-1,3-benzenedimethanamine;

(rr) AMD7136, N,N'-bis(2-pyridinylmethyl)-N-[1-[3-(2-chlorophenyl)-5-methyl-isoxazol-4-oyl]-4-piperidinyl]-1,3-benzenedimethanamine;

(ss) AMD7138, N-[(2-hydroxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-1,4-benzenedimethanamine;

(tt) AMD7140, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-1,4-benzenedimethanamine;

(uu) AMD7141, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(vv) AMD7142, N-[(4-acetamidophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(ww) AMD7145, N-[(4-phenoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-1,4-benzenedimethanamine;

(xx) AMD7147, N-[(1-methyl-2-carboxamido)ethyl]-N,N'-bis(2-pyridinylmethyl)-1,3-benzenedimethanamine;

(yy) AMD7151, N-[(4-benzyloxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-1,4-benzenedimethanamine; and

(zz) AMD7155, N-[(thiophene-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-1,4-benzenedimethanamine.

102. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.

119. (Amended) A compound of the formula



$$Y\text{—}W(X)(Z)(CR^1R^2)_nArCR^3R^4N(R^5)(CR^6R^7)_nR^8 \qquad (I)$$

wherein, W is a nitrogen atom and Y is void;

R^1 to R^7 may be the same or different and are independently hydrogen or straight, branched or cyclic C_{1-6} alkyl;

R^8 is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in ring A or B is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a $(CH_2)_{n''}$ group (where n''= 1-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C_{1-6} alkyl group; an optionally substituted aromatic or heterocyclic group; a C_{1-6} alkyl group substituted with an optionally substituted aromatic or heterocyclic group; an optionally substituted amino group; an optionally substituted C_{1-6} alkylamino or C_{3-7} cycloalkylamino group; a sulfonyl group and an optionally substituted carbonyl group; or the pharmaceutically acceptable acid addition salts thereof;

including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof.

120. The compound of claim 119, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

121. The compound of claim 119, wherein Ring B is selected from the group consisting of: benzene and a 5 to 7–membered cycloalkyl ring; and the optionally substituted forms thereof.

122. The compound of claim 119, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

123. The compound of claim 119, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

124. The compound of claim 119, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

125. (Amended) The compound of claim 119 wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

126. The compound of claim 125, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC_{1-4}alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

127. The compound of claim 119, wherein Z is an optionally substituted C_{1-6}alkyl group, wherein said C_{1-6}alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

128. The compound of claim 119, wherein Z is an optionally substituted aromatic or heterocyclic group or a C_{1-6}alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

129. (Amended) The compound of claim 128, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

130. The compound of claim 129, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole, benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole, oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline, piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine, imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

131. (Amended) The compound of claim 130, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

132. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 119 in admixture with at least one pharmaceutically acceptable excipient.